These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22252020)

  • 21. Platelet function recovery after cessation of aspirin: preliminary study of volunteers and surgical patients.
    Zisman E; Erport A; Kohanovsky E; Ballagulah M; Cassel A; Quitt M; Pizov R
    Eur J Anaesthesiol; 2010 Jul; 27(7):617-23. PubMed ID: 20035230
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Response to aspirin in healthy individuals. Cross-comparison of light transmission aggregometry, VerifyNow system, platelet count drop, thromboelastography (TEG) and urinary 11-dehydrothromboxane B(2).
    Blais N; Pharand C; Lordkipanidzé M; Sia YK; Merhi Y; Diodati JG
    Thromb Haemost; 2009 Aug; 102(2):404-11. PubMed ID: 19652893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin.
    Watala C; Pluta J; Golanski J; Rozalski M; Czyz M; Trojanowski Z; Drzewoski J
    J Mol Med (Berl); 2005 Feb; 83(2):148-58. PubMed ID: 15723265
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Insights into the inhibition of platelet activation by omega-3 polyunsaturated fatty acids: beyond aspirin and clopidogrel.
    Cohen MG; Rossi JS; Garbarino J; Bowling R; Motsinger-Reif AA; Schuler C; Dupont AG; Gabriel D
    Thromb Res; 2011 Oct; 128(4):335-40. PubMed ID: 21621252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment with high-dose n-3 PUFAs has no effect on platelet function, coagulation, metabolic status or inflammation in patients with atherosclerosis and type 2 diabetes.
    Poreba M; Mostowik M; Siniarski A; Golebiowska-Wiatrak R; Malinowski KP; Haberka M; Konduracka E; Nessler J; Undas A; Gajos G
    Cardiovasc Diabetol; 2017 Apr; 16(1):50. PubMed ID: 28410617
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry.
    Nielsen HL; Kristensen SD; Thygesen SS; Mortensen J; Pedersen SB; Grove EL; Hvas AM
    Thromb Res; 2008; 123(2):267-73. PubMed ID: 18499236
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of aspirin intake at bedtime versus on awakening on circadian rhythm of platelet reactivity. A randomised cross-over trial.
    Bonten TN; Saris A; van Oostrom MJ; Snoep JD; Rosendaal FR; Zwaginga J; Eikenboom J; van der Meer PF; van der Bom JG
    Thromb Haemost; 2014 Dec; 112(6):1209-18. PubMed ID: 25208590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial.
    Paikin JS; Hirsh J; Ginsberg JS; Weitz JI; Chan NC; Whitlock RP; Pare G; Johnston M; Eikelboom JW
    J Thromb Haemost; 2015 Mar; 13(3):448-56. PubMed ID: 25546465
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Do statins influence platelet reactivity on acetylsalicylic acid therapy in patients with type 2 diabetes?
    Postula M; Rosiak M; Kaplon-Cieslicka A; Kondracka A; Trzepla E; Filipiak KJ; Czlonkowski A; Opolski G
    Cardiol J; 2012; 19(5):494-500. PubMed ID: 23042313
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatty acids and TxA(2) generation, in the absence of platelet-COX-1 activity.
    DeFilippis AP; Rai SN; Cambon A; Miles RJ; Jaffe AS; Moser AB; Jones RO; Bolli R; Schulman SP
    Nutr Metab Cardiovasc Dis; 2014 Apr; 24(4):428-33. PubMed ID: 24370448
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced antiplatelet effect of aspirin during 24 hours in patients with coronary artery disease and type 2 diabetes.
    Christensen KH; Grove EL; Würtz M; Kristensen SD; Hvas AM
    Platelets; 2015; 26(3):230-5. PubMed ID: 24750015
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incremental role of glycaemic variability over HbA1c in identifying type 2 diabetic patients with high platelet reactivity undergoing percutaneous coronary intervention.
    Nusca A; Tuccinardi D; Proscia C; Melfi R; Manfrini S; Nicolucci A; Ceriello A; Pozzilli P; Ussia GP; Grigioni F; Di Sciascio G
    Cardiovasc Diabetol; 2019 Nov; 18(1):147. PubMed ID: 31706305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of obesity on platelet reactivity and response to low-dose aspirin.
    Bordeaux BC; Qayyum R; Yanek LR; Vaidya D; Becker LC; Faraday N; Becker DM
    Prev Cardiol; 2010; 13(2):56-62. PubMed ID: 20377806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control.
    Watala C; Golanski J; Pluta J; Boncler M; Rozalski M; Luzak B; Kropiwnicka A; Drzewoski J
    Thromb Res; 2004; 113(2):101-13. PubMed ID: 15115665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status.
    Thomas MR; Angiolillo DJ; Bonaca MP; Ajjan RA; Judge HM; Rollini F; Franchi F; Ahsan AJ; Bhatt DL; Kuder JF; Steg PG; Cohen M; Muthusamy R; Sabatine MS; Storey RF
    Thromb Haemost; 2017 May; 117(5):940-947. PubMed ID: 28300867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus.
    Ertugrul DT; Tutal E; Yildiz M; Akin O; Yalçin AA; Ure OS; Yilmaz H; Yavuz B; Deveci OS; Ata N; Küçükazman M
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2897-901. PubMed ID: 20382685
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
    Renda G; Tacconelli S; Capone ML; Sacchetta D; Santarelli F; Sciulli MG; Zimarino M; Grana M; D'Amelio E; Zurro M; Price TS; Patrono C; De Caterina R; Patrignani P
    Clin Pharmacol Ther; 2006 Sep; 80(3):264-74. PubMed ID: 16952493
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A comparison of VerifyNowR with PlateletMappingR--detected aspirin resistance and correlation with urinary thromboxane.
    Carroll RC; Craft RM; Snider CC; Aligeti VR; Wortham DC
    Anesth Analg; 2013 Feb; 116(2):282-6. PubMed ID: 23302970
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cigarette smoking is associated with a dose-response effect in clopidogrel-treated patients with diabetes mellitus and coronary artery disease: results of a pharmacodynamic study.
    Ueno M; Ferreiro JL; Desai B; Tomasello SD; Tello-Montoliu A; Capodanno D; Capranzano P; Kodali M; Dharmashankar K; Charlton RK; Bass TA; Angiolillo DJ
    JACC Cardiovasc Interv; 2012 Mar; 5(3):293-300. PubMed ID: 22440495
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.